By Fineline Cube Harbour BioMed (HKG: 2142) announced that the first patient has been dosed in the Phase II SIRIUS clinical study evaluating HBM9378/WIN378 (SKB378) for chronic obstructive pulmonary disease (COPD), conducted by its Swiss partner Windward Bio.
HBM9378/WIN378 is a next-generation fully human monoclonal antibody that potently inhibits the thymic stromal lymphopoietin (TSLP) ligand, a clinically validated target central to the pathogenesis of multiple immune-mediated diseases including asthma and COPD. The antibody has been engineered with extended half-life and silenced effector function, enabling a potential once-every-six-month dosing regimen—a significant advantage over current biologic therapies requiring monthly or quarterly administration.
Technology Platform & Clinical Profile
Engineered Antibody Features
- Target: Thymic stromal lymphopoietin (TSLP) ligand inhibition
- Half-Life Extension: Significantly prolonged pharmacokinetics supporting biannual dosing
- Effector Function: Silenced Fc region minimizing potential inflammatory side effects
- Immunogenicity: Low rates of anti-drug antibodies demonstrated in Phase I studies
- Safety Profile: Favorable tolerability even at highest tested doses
Phase I Clinical Results
| Parameter | Outcome |
|---|---|
| Half-Life | Significantly prolonged vs. standard monoclonal antibodies |
| Dosing Frequency | Once every six months (potential) |
| Immunogenicity | Low anti-drug antibody rates |
| Safety | Favorable profile at maximum tolerated doses |
| Tolerability | Well-tolerated across dose ranges |
Strategic Partnership Structure
Licensing Agreement Details
- Partners: Windward Bio (Switzerland), Harbour BioMed, and Kelun-Biotech
- Territory: Global rights excluding Greater China and select Southeast Asian/West Asian countries
- Development Responsibility: Windward Bio leading global clinical development
- Commercial Rights: Windward Bio holds worldwide commercialization rights in licensed territories
- Retention Rights: Harbour BioMed and Kelun-Biotech retain full rights in Greater China
Geographic Allocation
- Windward Bio: North America, Europe, Latin America, Japan, Australia, and other major markets
- Harbour BioMed/Kelun-Biotech: Mainland China, Hong Kong, Macau, Taiwan, plus specified Asian territories
Market Opportunity & Competitive Landscape
COPD Therapeutic Landscape
- Global Burden: COPD affects over 300 million people worldwide with limited biologic options
- Current Biologics: Primarily focused on asthma; limited COPD-specific biologic approvals
- TSLP Validation: Clinically proven target with tezepelumab approval in asthma demonstrating pathway viability
- Dosing Advantage: Biannual regimen represents significant improvement over monthly/quarterly competitors
Competitive Differentiation
- Dosing Convenience: Only TSLP inhibitor potentially offering twice-yearly administration
- Engineered Optimization: Enhanced half-life and safety profile through protein engineering
- Dual Indication Potential: Applicable to both asthma and COPD, expanding addressable market
- Partnership Strength: Windward Bio’s European expertise complements Chinese innovation
Commercial Implications & Revenue Outlook
- Market Size: Global COPD biologics market projected to reach $8-12 billion by 2030
- Pricing Strategy: Premium positioning based on dosing convenience and engineered advantages
- Revenue Structure: Milestone payments and tiered royalties from Windward Bio partnership
- Peak Sales Potential: Analysts estimate $500-800 million in annual global sales for TSLP inhibitors in COPD
- Franchise Expansion: Success in COPD could accelerate development in other TSLP-mediated conditions
This Phase II initiation represents a critical milestone in developing a potentially best-in-class TSLP inhibitor that could redefine treatment paradigms for chronic respiratory diseases through unprecedented dosing convenience and optimized safety profile.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, partnership execution, and revenue projections. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics in the respiratory therapeutics market.-Fineline Info & Tech